Aurinia's LUPKYNIS™ (voclosporin) update published in The Lancet
Aurinia Pharmaceuticals published results from a phase 3 AURORA 1 study today, which evaluates LUPKYNIS™ (voclosporin), an FDA-approved treatment for lupus nephritis (LN). Results were published in The Lancet, an international, peer-reviewed medical journal.
Per Aurinia: "The AURORA 1 study results demonstrate that LUPKYNIS in combination with mycophenolate mofetil (MMF) and low-dose corticosteroids led to statistically superior complete renal response rates at 52 weeks compared to treatment with MMF and low-dose corticosteroids alone, with a comparable safety profile. In fact, separation in efficacy between treatment groups was observed as early as 4 weeks. MMF and corticosteroids are typical SoC immunosuppressive agents used for the treatment of LN.
“Lupus nephritis can be a devastating condition if not diagnosed and managed early,” stated Brad H. Rovin, M.D., Professor of Medicine and the Director of the Division of Nephrology, Ohio State University Wexler Medical Center, an AURORA clinical trial investigator and the lead author of the publication. “The publication of AURORA 1 data validates the importance of voclosporin (LUPKYNIS) in early disease intervention for LN. These data establish voclosporin as an efficacious and safe, rapid-acting new treatment option for patients in need.”
Lupkynis was approved by the Food and Drug Administration for LN treatment earlier this year. Consult your physician before making changes to your medication and continue to follow the Lupus Foundation of America for updates on voclosporin.